Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €16.43 EUR
Change Today -0.055 / -0.33%
Volume 0.0
A8D On Other Exchanges
Symbol
Exchange
EN Paris
Frankfurt
OTC US
As of 2:23 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

ab science sa (A8D) Snapshot

Open
€16.43
Previous Close
€16.49
Day High
€16.43
Day Low
€16.43
52 Week High
02/10/15 - €17.86
52 Week Low
10/17/14 - €7.14
Market Cap
549.3M
Average Volume 10 Days
98.5
EPS TTM
--
Shares Outstanding
33.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AB SCIENCE SA (A8D)

Related News

No related news articles were found.

ab science sa (A8D) Related Businessweek News

No Related Businessweek News Found

ab science sa (A8D) Details

AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. The company markets Masitinib for the treatment of oncology and inflammatory diseases for dogs and cats. It markets its Masitinib under the Masivet brand name in Europe; and Kinavet brand name in the United States. The company is also developing Masitinib in human indications that are in various Phase II and Phase III clinical trials for the treatment of oncology, inflammatory, hematology, and central nervous system diseases, as well as for the treatment of indolent systemic mastocytosis, non controlled severe asthma, refractory rheumatoid arthritis, progressive forms of multiple sclerosis, amyothrophic lateral sclerosis, and Alzheimer's diseases. It serves hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

121 Employees
Last Reported Date: 04/30/15
Founded in 2001

ab science sa (A8D) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: €456.7K
Compensation as of Fiscal Year 2013.

ab science sa (A8D) Key Developments

AB Science S.A. - Special Call

To discuss on masitinib in the treatment of amyotrophic lateral sclerosis (ALS) with key opinion leaders from this disease, the current positioning of masitinib in ALS, the scientific rationale for developing masitinib in ALS, the efficacy and safety update on the on-going phase 3 study and the market potential for masitinib in ALS

AB Science S.A. Announces the Publication of Results from the First Randomized Phase 3 Study of Masitinib in Treatment of Advanced Pancreatic Ductal Adenocarcinoma

AB Science S.A. announced the publication of results from the first randomized phase 3 study of masitinib in treatment of advanced pancreatic ductal adenocarcinoma (PDAC). In patients with over-expression of ACOX1 in blood, administration of masitinib in combination with Gemzar produced a statistically significant overall survival advantage of +6.1 months (Hazard Ratio=0.23[0.10;0.51]) when compared with placebo administered in combination with Gemzar. In the pain subgroup, administration of masitinib in combination with Gemzar produced a statistically significant overall survival advantage of +2.6 months (Hazard Ratio=0.62[0.43;0.89]) when compared with placebo administered in combination with Gemzar. Safety of the combination remained acceptable with no overall detrimental effect on quality of life. A new confirmatory phase 3 trial of masitinib in advanced pancreatic cancer has been initiated, with an objective to replicate these promising results in a prospective manner.

AB Science's Masitinib Receives Orphan Drug Designation for Amyotrophic Lateral Sclerosis from FDA

AB Science SA announced that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug designation for masitinib in the treatment of amyotrophic lateral sclerosis. The FDA's Office of Orphan Drug Products Development reviews applications for Orphan Drug status to support development of medicines for underserved patient populations, or rare disorders that affect fewer than 200,000 people in the United States. The successful application submitted by AB Science and the FDA granting of Orphan Drug status entitles the company to a seven-year period of marketing exclusivity in the United States for masitinib, if it is approved by the FDA for the treatment of amyotrophic lateral sclerosis. Orphan Drug status also enables the company to apply for research grant funding for Phase I and II Clinical Trials, tax credits for certain research expenses, and a waiver from the FDA's application user fee, as well as additional support from FDA and a potentially faster regulatory process. A phase 3 is currently on-going with masitinib in ALS. In January 2015, the external Data and Safety Monitoring Board (DSMB) recommended the continuation of this phase 3 study based upon review of the latest safety data. The DSMB was created as part of the company's pivotal clinical study evaluating masitinib in the treatment of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis is a rare degenerative disorder that results in progressive wasting and paralysis of voluntary muscles. There are approximately 30,000 people with ALS in the European Union and 15,000 in the US, with more than 7,500 new cases diagnosed each year in Europe and 4,500 in the US. Almost 50% of ALS patients die within 3 years and 90% die within 5 years.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
A8D:GR €16.43 EUR -0.055

A8D Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for A8D.
View Industry Companies
 

Industry Analysis

A8D

Industry Average

Valuation A8D Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 235.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 218.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AB SCIENCE SA, please visit www.ab-science.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.